Abbott(ABT)
ABBOTT PARK, IL
Biotechnology1 H-1B visas (FY2023)Focus: Device Manufacturing
Abbott is a life sciences company focused on Device Manufacturing.
CardiovascularImmunologyNeurologyMetabolic DiseasesOncology
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (50)
A-HYDROCORT
hydrocortisone sodium succinate
Post-LOE
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems. Hydrocortisone sodium succinate has the same metabolic and anti-inflammatory actions as hydrocortisone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. The highly water-soluble sodium succinate ester of hydrocortisone permits the immediate intravenous administration of high doses of hydrocortisone in a small volume of diluent and is particularly useful where high blood levels of hydrocortisone are required rapidly. Following the intravenous injection of hydrocortisone sodium succinate, demonstrable effects are evident within one hour and persist for a variable period. Excretion of the administered dose is nearly complete within 12 hours. Thus, if constantly high blood levels are required, injections should be made every 4 to 6 hours. This preparation is also rapidly absorbed when administered intramuscularly and is excreted in a pattern similar to that observed after intravenous injection. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune response to diverse stimuli.
dermatomyositistemporal arteritispolymyositis+14 more
1978
30
A-HYDROCORT
hydrocortisone sodium succinate
Pre-Launch
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems. Hydrocortisone sodium succinate has the same metabolic and anti-inflammatory actions as hydrocortisone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. The highly water-soluble sodium succinate ester of hydrocortisone permits the immediate intravenous administration of high doses of hydrocortisone in a small volume of diluent and is particularly useful where high blood levels of hydrocortisone are required rapidly. Following the intravenous injection of hydrocortisone sodium succinate, demonstrable effects are evident within one hour and persist for a variable period. Excretion of the administered dose is nearly complete within 12 hours. Thus, if constantly high blood levels are required, injections should be made every 4 to 6 hours. This preparation is also rapidly absorbed when administered intramuscularly and is excreted in a pattern similar to that observed after intravenous injection. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune response to diverse stimuli.
dermatomyositistemporal arteritispolymyositis+14 more
A-HYDROCORT
hydrocortisone sodium succinate
Pre-Launch
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems. Hydrocortisone sodium succinate has the same metabolic and anti-inflammatory actions as hydrocortisone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. The highly water-soluble sodium succinate ester of hydrocortisone permits the immediate intravenous administration of high doses of hydrocortisone in a small volume of diluent and is particularly useful where high blood levels of hydrocortisone are required rapidly. Following the intravenous injection of hydrocortisone sodium succinate, demonstrable effects are evident within one hour and persist for a variable period. Excretion of the administered dose is nearly complete within 12 hours. Thus, if constantly high blood levels are required, injections should be made every 4 to 6 hours. This preparation is also rapidly absorbed when administered intramuscularly and is excreted in a pattern similar to that observed after intravenous injection. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune response to diverse stimuli.
dermatomyositistemporal arteritispolymyositis+14 more
A-HYDROCORT
hydrocortisone sodium succinate
Pre-Launch
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems. Hydrocortisone sodium succinate has the same metabolic and anti-inflammatory actions as hydrocortisone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. The highly water-soluble sodium succinate ester of hydrocortisone permits the immediate intravenous administration of high doses of hydrocortisone in a small volume of diluent and is particularly useful where high blood levels of hydrocortisone are required rapidly. Following the intravenous injection of hydrocortisone sodium succinate, demonstrable effects are evident within one hour and persist for a variable period. Excretion of the administered dose is nearly complete within 12 hours. Thus, if constantly high blood levels are required, injections should be made every 4 to 6 hours. This preparation is also rapidly absorbed when administered intramuscularly and is excreted in a pattern similar to that observed after intravenous injection. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune response to diverse stimuli.
dermatomyositistemporal arteritispolymyositis+14 more
A-HYDROCORT
hydrocortisone sodium succinate
Pre-Launch
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems. Hydrocortisone sodium succinate has the same metabolic and anti-inflammatory actions as hydrocortisone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. The highly water-soluble sodium succinate ester of hydrocortisone permits the immediate intravenous administration of high doses of hydrocortisone in a small volume of diluent and is particularly useful where high blood levels of hydrocortisone are required rapidly. Following the intravenous injection of hydrocortisone sodium succinate, demonstrable effects are evident within one hour and persist for a variable period. Excretion of the administered dose is nearly complete within 12 hours. Thus, if constantly high blood levels are required, injections should be made every 4 to 6 hours. This preparation is also rapidly absorbed when administered intramuscularly and is excreted in a pattern similar to that observed after intravenous injection. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune response to diverse stimuli.
dermatomyositistemporal arteritispolymyositis+14 more
A-METHAPRED
methylprednisolone sodium succinate
Post-LOE
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. Methylprednisolone is a potent anti-inflammatory steroid with greater anti-inflammatory potency than prednisolone and even less tendency than prednisolone to induce sodium and water retention. Methylprednisolone sodium succinate has the same metabolic and anti-inflammatory actions as methylprednisolone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. Following the intravenous injection of methylprednisolone sodium succinate, demonstrable effects are evident within one hour and persist for a variable period. Excretion of the administered dose is nearly complete within 12 hours. Thus, if constantly high blood levels are required, injections should be made every 4 to 6 hours. This preparation is also rapidly absorbed when administered intramuscularly and is excreted in a pattern similar to that observed after intravenous injection.
dermatomyositistemporal arteritispolymyositis+15 more
1991
30
A-METHAPRED
methylprednisolone sodium succinate
Post-LOE
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. Methylprednisolone is a potent anti-inflammatory steroid with greater anti-inflammatory potency than prednisolone and even less tendency than prednisolone to induce sodium and water retention. Methylprednisolone sodium succinate has the same metabolic and anti-inflammatory actions as methylprednisolone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. Following the intravenous injection of methylprednisolone sodium succinate, demonstrable effects are evident within one hour and persist for a variable period. Excretion of the administered dose is nearly complete within 12 hours. Thus, if constantly high blood levels are required, injections should be made every 4 to 6 hours. This preparation is also rapidly absorbed when administered intramuscularly and is excreted in a pattern similar to that observed after intravenous injection.
dermatomyositistemporal arteritispolymyositis+15 more
1991
30
A-METHAPRED
methylprednisolone sodium succinate
Post-LOE
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. Methylprednisolone is a potent anti-inflammatory steroid with greater anti-inflammatory potency than prednisolone and even less tendency than prednisolone to induce sodium and water retention. Methylprednisolone sodium succinate has the same metabolic and anti-inflammatory actions as methylprednisolone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. Following the intravenous injection of methylprednisolone sodium succinate, demonstrable effects are evident within one hour and persist for a variable period. Excretion of the administered dose is nearly complete within 12 hours. Thus, if constantly high blood levels are required, injections should be made every 4 to 6 hours. This preparation is also rapidly absorbed when administered intramuscularly and is excreted in a pattern similar to that observed after intravenous injection.
dermatomyositistemporal arteritispolymyositis+15 more
1991
30
A-METHAPRED
methylprednisolone sodium succinate
Post-LOE
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. Methylprednisolone is a potent anti-inflammatory steroid with greater anti-inflammatory potency than prednisolone and even less tendency than prednisolone to induce sodium and water retention. Methylprednisolone sodium succinate has the same metabolic and anti-inflammatory actions as methylprednisolone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. Following the intravenous injection of methylprednisolone sodium succinate, demonstrable effects are evident within one hour and persist for a variable period. Excretion of the administered dose is nearly complete within 12 hours. Thus, if constantly high blood levels are required, injections should be made every 4 to 6 hours. This preparation is also rapidly absorbed when administered intramuscularly and is excreted in a pattern similar to that observed after intravenous injection.
dermatomyositistemporal arteritispolymyositis+15 more
1991
30
A-POXIDE
chlordiazepoxide hydrochloride
Post-LOE
ORAL · CAPSULE
CLINICAL PHARMACOLOGY Chlordiazepoxide HCl has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The precise mechanism of action is not known. The drug blocks EEG arousal from stimulation of the brain stem reticular formation. It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours. After the drug is discontinued plasma levels decline slowly over a period of several days. Chlordiazepoxide is excreted in the urine, with 1% to 2% unchanged and 3% to 6% as a conjugate. Animal Pharmacology The drug has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses. Hostile monkeys were made tame by oral drug doses which did not cause sedation. Chlordiazepoxide HCl revealed a "taming" action with the elimination of fear and aggression. The taming effect of chlordiazepoxide HCl was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals. The LD 50 of parenterally administered chlordiazepoxide HCl was determined in mice (72 hours) and rats (5 days), and calculated according to the method of Miller and Tainter, with the following results: mice, IV, 123 ± 12 mg/kg; mice, IM, 366 ± 7 mg/kg; rats, IV, 120 ± 7 mg/kg; rats, IM, > 160 mg/kg. Effects on Reproduction Reproduction studies in rats fed 10, 20 and 80 mg/kg daily and bred through one or two matings showed no congenital anomalies, nor were there adverse effects on lactation of the dams or growth of the newborn. However, in another study at 100 mg/kg daily there was noted a significant decrease in the fertilization rate and a marked decrease in the viability and body weight of offspring which may be attributable to sedative activity, thus resulting in lack of interest in mating and lessened maternal nursing and care of the young. One neonate in each of the first and second matings in the rat reproduction study at the 100 mg/kg dose exhibited major skeletal defects. Further studies are in progress to determine the significance of these findings.
anxiety disordersfor the short term relief of symptoms of anxietywithdrawal symptoms of acute alcoholism+2 more
1977
30
A-POXIDE
chlordiazepoxide hydrochloride
Post-LOE
ORAL · CAPSULE
CLINICAL PHARMACOLOGY Chlordiazepoxide HCl has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The precise mechanism of action is not known. The drug blocks EEG arousal from stimulation of the brain stem reticular formation. It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours. After the drug is discontinued plasma levels decline slowly over a period of several days. Chlordiazepoxide is excreted in the urine, with 1% to 2% unchanged and 3% to 6% as a conjugate. Animal Pharmacology The drug has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses. Hostile monkeys were made tame by oral drug doses which did not cause sedation. Chlordiazepoxide HCl revealed a "taming" action with the elimination of fear and aggression. The taming effect of chlordiazepoxide HCl was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals. The LD 50 of parenterally administered chlordiazepoxide HCl was determined in mice (72 hours) and rats (5 days), and calculated according to the method of Miller and Tainter, with the following results: mice, IV, 123 ± 12 mg/kg; mice, IM, 366 ± 7 mg/kg; rats, IV, 120 ± 7 mg/kg; rats, IM, > 160 mg/kg. Effects on Reproduction Reproduction studies in rats fed 10, 20 and 80 mg/kg daily and bred through one or two matings showed no congenital anomalies, nor were there adverse effects on lactation of the dams or growth of the newborn. However, in another study at 100 mg/kg daily there was noted a significant decrease in the fertilization rate and a marked decrease in the viability and body weight of offspring which may be attributable to sedative activity, thus resulting in lack of interest in mating and lessened maternal nursing and care of the young. One neonate in each of the first and second matings in the rat reproduction study at the 100 mg/kg dose exhibited major skeletal defects. Further studies are in progress to determine the significance of these findings.
anxiety disordersfor the short term relief of symptoms of anxietywithdrawal symptoms of acute alcoholism+2 more
1977
30
A-POXIDE
chlordiazepoxide hydrochloride
Post-LOE
ORAL · CAPSULE
CLINICAL PHARMACOLOGY Chlordiazepoxide HCl has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The precise mechanism of action is not known. The drug blocks EEG arousal from stimulation of the brain stem reticular formation. It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours. After the drug is discontinued plasma levels decline slowly over a period of several days. Chlordiazepoxide is excreted in the urine, with 1% to 2% unchanged and 3% to 6% as a conjugate. Animal Pharmacology The drug has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses. Hostile monkeys were made tame by oral drug doses which did not cause sedation. Chlordiazepoxide HCl revealed a "taming" action with the elimination of fear and aggression. The taming effect of chlordiazepoxide HCl was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals. The LD 50 of parenterally administered chlordiazepoxide HCl was determined in mice (72 hours) and rats (5 days), and calculated according to the method of Miller and Tainter, with the following results: mice, IV, 123 ± 12 mg/kg; mice, IM, 366 ± 7 mg/kg; rats, IV, 120 ± 7 mg/kg; rats, IM, > 160 mg/kg. Effects on Reproduction Reproduction studies in rats fed 10, 20 and 80 mg/kg daily and bred through one or two matings showed no congenital anomalies, nor were there adverse effects on lactation of the dams or growth of the newborn. However, in another study at 100 mg/kg daily there was noted a significant decrease in the fertilization rate and a marked decrease in the viability and body weight of offspring which may be attributable to sedative activity, thus resulting in lack of interest in mating and lessened maternal nursing and care of the young. One neonate in each of the first and second matings in the rat reproduction study at the 100 mg/kg dose exhibited major skeletal defects. Further studies are in progress to determine the significance of these findings.
anxiety disordersfor the short term relief of symptoms of anxietywithdrawal symptoms of acute alcoholism+2 more
1977
30
Pipeline & Clinical Trials
Home-based Exercise Rehabilitation.
Heart FailureClinical Trials (1)
NCT04942353Effects of Home-based Exercise Rehabilitation on Healthcare Utilization in HeartMate 3 Patients
N/AAlinity m HR HPV
Human PapillomavirusClinical Trials (1)
NCT04746872Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening
N/AEffectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of
HypertensionClinical Trials (1)
NCT01079195Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus
N/ACRT with MultiPoint Pacing
Heart FailureClinical Trials (1)
NCT02064751MultiPoint Pacing Programming Guided by Noninvasive Hemodynamics
N/AAveir VR Leadless Pacemaker System
Cardiac PacemakerClinical Trials (3)
NCT05270499Aveir VR Real-World Evidence Post-Approval Study
N/ANCT05336877Aveir VR Coverage With Evidence Development Post-Approval Study
N/ANCT04559945The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System
N/AEvaluation of Effectiveness and Safety of XIENCE PRIME Stent (IRIS-PRIME)
Coronary Artery DiseaseClinical Trials (1)
NCT01348399Evaluation of Effectiveness and Safety of XIENCE PRIME Stent (IRIS-PRIME)
N/AImplantation with the commercially available Axium Neurostimulator
Chronic PainClinical Trials (5)
NCT02335489A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Neuropathic Pain of the Foot and/or Lower Leg
N/ANCT02169401A Multi-centre Observational Study of the Axium Neurostimulator as a Treatment for Chronic Pain
N/ANCT02346656a BavaRiAn eValuatiOn of Dorsal Root Ganglion (DRG) Stimulation for the Treatment for Chronic Post Surgical Pain of the Groin
N/A+2 more
Thoracic MRI Scan
ICDClinical Trials (1)
NCT02877693A Post-market Clinical Evaluation of St. Jude Medical™ MR Conditional ICD System on Patients Undergoing Magnetic Resonance Imaging
N/ABrain Injury Assessment Study at Hennepin County Medical Center
Traumatic Brain InjuryClinical Trials (1)
NCT02706574Brain Injury Assessment Study at Hennepin County Medical Center
N/AHuman Milk Fortifier A
Infant GrowthClinical Trials (1)
NCT02307760Evaluation of Human Milk Fortifiers in Preterm Infants
N/ACGM device with diabetic education, CGM education and a follow up protocol.
Diabetes Mellitus, Type 2Clinical Trials (1)
NCT04729985Diabetes Discharge Transitional CGM Study (DDT-CGM)
N/ANutritional Status of Cerebral Palsy Patients in Turkey
Nutritional StatusClinical Trials (1)
NCT02589704Nutritional Status of Cerebral Palsy Patients in Turkey
N/AProlonged Monitoring to Detect Ventricular Arrhythmias in Presymptomatic Arrhythmogenic Right Ventri
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)Clinical Trials (1)
NCT01271816Prolonged Monitoring to Detect Ventricular Arrhythmias in Presymptomatic Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Patients
N/APacemaker implantation with RA lead in LAS position
Atrial FibrillationClinical Trials (1)
NCT00419640SAFE Study - Septal Pacing for Atrial Fibrillation Suppression Evaluation
N/AEverolimus Eluting BVS
AtherosclerosisClinical Trials (1)
NCT01341340The ABSORB BTK (Below The Knee) Clinical Investigation
N/ADetermining When Patients Hospitalized With Acute Heart Failure Can Be Safely Sent Home (The DECIDE
Acute Heart FailureClinical Trials (1)
NCT00911703Determining When Patients Hospitalized With Acute Heart Failure Can Be Safely Sent Home (The DECIDE Study)
N/AMPP + SyncAV
Cardiac Resynchronization TherapyClinical Trials (1)
NCT06444386ECGi of SyncAV With MultiPoint Pacing
N/AAveir DR Leadless Pacemaker System
Cardiac PacemakerClinical Trials (1)
NCT05932602AVEIR DR Coverage With Evidence Development (CED) Study
N/AGreek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimum
Rheumatoid ArthritisClinical Trials (1)
NCT01282372Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
N/AFreeStyle Libre 2 Flash Glucose Monitoring System
Type 2 Diabetes Treated With InsulinClinical Trials (4)
NCT04577976FreeStyle Libre 2 Flash Glucose Monitoring System Control Phase Study for Pediatric Patients - BG
N/ANCT06268808Initiation of Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin, in Italy
N/ANCT05168306T2 FSL2 Weight Loss
N/A+1 more
Preterm infant formula per standard of care
Other Preterm InfantsClinical Trials (1)
NCT02073071Effects of Infant Formula on the Growth and Tolerance in Preterm/Low Birth Weight Infants
N/AWarfarin
Heart FailureClinical Trials (4)
NCT02836652Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy
Phase 4NCT04865978Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices
Phase 2NCT03704220Anti-thrombotic Monotherapy With the HeartMate 3 LVAS
N/A+1 more
Multi-purpose disinfecting solution
Normal Contact Lens WearersClinical Trials (2)
NCT01847105Assessing Patient Comfort With Two Different Multi-Purpose Disinfecting Solutions
N/ANCT01294917Comparison of a New Abbott Medical Optics (AMO) Multi-Purpose Solution (MPS) to Existing Contact Lens Regimens
N/AVascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery
Vascular DeathClinical Trials (1)
NCT01842568Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery
N/ALIBERATE
Diabetes Mellitus, Type 2Clinical Trials (1)
NCT05261906The FreeStyle Libre Enabled Reduction of A1c Through Effective Eating and Exercise Study
N/ASubstrate+mCPVA
Persistent Atrial FibrillationClinical Trials (1)
NCT02571218AF Substrate Mapping and Guided Ablation
N/Abirth dose vaccination against hepatitis B strategy
Hepatitis BSJM Confirm ICM
Atrial FibrillationClinical Trials (1)
NCT01673256DEtermining Accuracy and TrEnding CharacTerization of AF
N/ASt. Jude Medical renal artery ablation system: RF ablation generator
HypertensionClinical Trials (1)
NCT01438229Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
N/ALBBAP with SyncAV
Heart FailureClinical Trials (1)
NCT06436053Acute Response to Left Bundle Branch Area Pacing With SyncAV
N/AStandard PVI Ablation
Persistent Atrial FibrillationClinical Trials (1)
NCT02274857Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures
N/AObservational study
Rheumatoid ArthritisClinical Trials (5)
NCT01855412Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes
N/ANCT01663896Observational Study of OCT in a Patients Undergoing FFR
N/ANCT06709001An Observational Study to Assess Malnutrition Risk
N/A+2 more
Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventr
AnticoagulationClinical Trials (1)
NCT01477528Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)
N/ADorsal root ganglion
Chronic PainClinical Trials (5)
NCT02587637Study to Evaluate the Effectiveness of DRG Stimulation for Discogenic Low Back Pain
N/ANCT02335229A Post Market Study to Assess the Spinal Modulation Dorsal Root Ganglion Stimulator System in Chronic Post Surgical Pain
N/ANCT02800863TARGET Post-Approval Study
N/A+2 more
Catechin Cohort 1
Biological AgingClinical Trials (1)
NCT03213340Effects of Phytonutrients Upon Muscle Perfusion in Response to Feeding
N/ADiamondback 360® Coronary OAS Micro Crown
CADClinical Trials (1)
NCT02132611Coronary Orbital Atherectomy System Study
N/ACoronary artery placement of a drug-eluting stent
Coronary DiseaseClinical Trials (1)
NCT01310309EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease
N/AQuality Improvement Program
MalnutritionClinical Trials (3)
NCT03011944Impact of a Nutrition Quality Improvement Program on Outcomes of Malnourished Patients
N/ANCT02262429Quality Improvement Program (QIP) to Reduce 30-Day Readmission in Malnourished Hospitalized Patients
N/ANCT04042987Nutrition-Focused Quality Improvement Program (QIP) Among Community Dwelling Malnourished Patients
N/APatients implanted with a St. Jude Medical pacemakers
Standard Bradycardia Pacing IndicationClinical Trials (1)
NCT02577887Advanced Bradycardia Device Feature Utilization and Clinical Outcomes II
N/AUser Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRat
Oral AnticoagulationClinical Trials (1)
NCT01036646User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity
N/AStudy to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Pati
Secondary HyperparathyroidismClinical Trials (1)
NCT01073462Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years
N/AJETi lower extremity arterial thrombosis
Arterial ThrombosisClinical Trials (1)
NCT04370691JETi Lower Extremity Arterial Thrombosis
N/AEndovascular treatment for PAD during medical care
Atherosclerosis ObliteransClinical Trials (1)
NCT03020290Long Superficial Femoral Artery Stenting With SuperA Interwoven Nitinol Stents
N/APrevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients
PsoriasisClinical Trials (1)
NCT01316224Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment
N/AAdministration of patient self-assessment
CataractClinical Trials (2)
NCT02203747Patient Perception of Visual Distortions
N/ANCT02146599Patient Perception of Visual Quality and Function
N/AExercise Training
Bladder CancerClinical Trials (1)
NCT05715684Patient-Centered Surgical Prehabilitation
N/AN/A
Clinical Trials (1)
NCT03415152A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy
N/AEnhanced Clinical Intervention
Bipolar DisorderClinical Trials (1)
NCT00211263Bipolar Disorder Research Study for Ages 12 and Older
N/AObservation / Data Collection
Atrial FibrillationClinical Trials (1)
NCT03041233ABLATOR Brazil - Ablation Observational Study (Registry)
N/ACSI pVAD System
Coronary Artery DiseaseClinical Trials (2)
NCT05695716CSI Percutaneous Ventricular Assist Device (pVAD) Second in Human Study
N/ANCT05315544Cardiovascular Systems Inc. (CSI) pVAD First in Human Study
N/AOpen Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 131 approved products, 174 clinical trials
Top TAs: Immunology, Oncology, Neurology
H-1B (2023): 1 approval
SEC Filings: 2 available
Portfolio Health
Pre-Launch68 (52%)
LOE Approaching35 (27%)
Post-LOE28 (21%)
131 total products
Therapeutic Area Focus
Immunology
9 marketed84 pipeline
Oncology
9 marketed53 pipeline
Neurology
15 marketed31 pipeline
Infectious Diseases
1 marketed34 pipeline
Cardiovascular
2 marketed18 pipeline
Nephrology
19 pipeline
Respiratory
9 marketed5 pipeline
Dermatology
9 marketed3 pipeline
Marketed
Pipeline
Financials (FY2025)
Revenue
$40.1B8%
R&D Spend
$2.7B(7%)5%
Net Income
$5.7BCash
$7.6BVisa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub